Ongoing clinical trials
Cancer
The Tidal study
Lymphoma
A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies
Cancer
Checkmate 7DX
Prostate cancer
A Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer - CheckMate 7DX
Cancer
Multiple Myeloma Study C16029
Myeloma
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies
Cancer
The Coastal Study
Haematology
A Phase 3, Randomized, Open-Label, Controlled Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma
Cancer
MCL study
Mantle Cell Lymphoma
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma
Cancer
MK-1026
Haematology
A Phase 2/3 Relapsed and/or Refractory Multiple Myeloma study
Cancer
Assure
Haematology
A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia
Cancer
DCISionRT® Registry
Breast cancer DCIS
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Cancer
Multiple Myeloma study CC-220
Myeloma
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
Cancer
Bruin CLL 321
Haematology
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated CLL/Small Lymphocytic Lymphoma
Cancer
Greco2
Pancreatic cancer
GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer
Breast cancer
LIT study
Breast cancer
Evaluation of LIT test as a marker for immunocompetence in chemotherapy